3D Bioprinting Market worth $3.3 billion by 2027

1
(No Transcript)
2
The global 3D Bioprinting Market is projected
to USD 3.3 billion by 2027 from USD 1.3 billion
in 2022, at a CAGR of 20.8 between 2022 and 2027.
3
The 3D Bioprinters segment accounted for
the largest share in the 3D Bioprinting market,
by component, during the forecast period. Based
on component, the 3D bioprinting market is
segmented into 3D bioprinters and bioinks. 3D
bioprinters accounted for the larger market share
in 2021. Technological advancements and the
growing demand for organ transplants are the
major factors driving the growth of this segment.
4
The Research applications subsegment
accounted for the largest share of the
application segment in the 3D Bioprinting market
in 2021.   Based on application, the 3D
bioprinting market is segmented into research
applications and clinical applications. The
research applications segment accounted for the
larger share of the 3D bioprinting market in
2021. The market for research applications is
further segmented into drug research,
regenerative medicine, and 3D cell culture. Among
these, the drug research segment accounted for
the largest share of the market in 2021, due to
the growing adoption of 3D bioprinting technology
by biopharmaceutical companies.
5
Key Market Player ICO Group AB (US),
Organovo Holdings Inc. (US), Allevi, Inc.
(part of 3D Systems, Inc.) (US), CollPlant
Biotechnologies Ltd. (Israel), regenHU
(Switzerland)